Yam Nath Paudel

Dr. Yam Nath Paudel

Neuropharmacology Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Life Sciences
Verified
Journal Article
Closed access
Enes AkyuzEnes Akyuz
Enes Akyuz
APAyse Kristina Polat
Ayse Kristina Polat
EEEce Eroglu
Ece Eroglu
IKIrem Kullu
Irem Kullu
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel

11 September 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel
MSMohamad F Shaikh
Mohamad F Shaikh
ACAyanabha Chakraborti
Ayanabha Chakraborti
YKYatinesh Kumari
Yatinesh Kumari
AAAngel Aledo-Serrano
Angel Aledo-Serrano
IOIekhsan Othman
Iekhsan Othman
High mobility group box protein 1 (HMGB1) is a ubiquitous nuclear protein released by glia and neurons upon inflammasome activation and activates receptor for advanced glycation end products (RAGE) and toll-like receptor (TLR) 4 on the target cells. HMGB1/TLR4 axis is a key initiator of neuroinflammation. In recent days, more attention has been paid to HMGB1 due to its contribution in traumatic brain injury (TBI), neuroinflammatory conditions, epileptogenesis, and cognitive impairments and has emerged as a novel target for those conditions. Nevertheless, HMGB1 has not been portrayed as a common prognostic biomarker for these HMGB1 mediated pathologies. The current review discusses the contribution of HMGB1/TLR4/RAGE signaling in several brain injury, neuroinflammation mediated disorders, epileptogenesis and cognitive dysfunctions and in the light of available evidence, argued the possibilities of HMGB1 as a common viable biomarker of the above mentioned neurological dysfunctions. Furthermore, the review also addresses the result of preclinical studies focused on HMGB1 targeted therapy by the HMGB1 antagonist in several ranges of HMGB1 mediated conditions and noted an encouraging result. These findings suggest HMGB1 as a potential candidate to be a common biomarker of TBI, neuroinflammation, epileptogenesis, and cognitive dysfunctions which can be used for early prediction and progression of those neurological diseases. Future study should explore toward the translational implication of HMGB1 which can open the windows of opportunities for the development of innovative therapeutics that could prevent several associated HMGB1 mediated pathologies discussed herein.

7 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
Christina PiperiChristina Piperi
Christina Piperi
IOIekhsan Othman
Iekhsan Othman
KAKhurram Aamir
Khurram Aamir
MSMohamad F Shaikh
Mohamad F Shaikh
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and a leading cause of dementia, with accumulation of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs) as defining pathological features. AD presents a serious global health concern with no cure to date, reflecting the complexity of its pathogenesis. Recent evidence indicates that neuroinflammation serves as the link between amyloid deposition, Tau pathology, and neurodegeneration. The high mobility group box 1 (HMGB1) protein, an initiator and activator of neuroinflammatory responses, has been involved in the pathogenesis of neurodegenerative diseases, including AD. HMGB1 is a typical damage-associated molecular pattern (DAMP) protein that exerts its biological activity mainly through binding to the receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4). RAGE and TLR4 are key components of the innate immune system that both bind to HMGB1. Targeting of HMGB1, RAGE, and TLR4 in experimental AD models has demonstrated beneficial effects in halting AD progression by suppressing neuroinflammation, reducing Aβ load and production, improving spatial learning, and inhibiting microglial stimulation. Herein, we discuss the contribution of HMGB1 and its receptor signaling in neuroinflammation and AD pathogenesis, providing evidence of its beneficial effects upon therapeutic targeting.

1 September 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
Christina PiperiChristina Piperi
Christina Piperi
Vinod BalasubramaniamVinod Balasubramaniam
Vinod Balasubramaniam
IOIekhsan Othman
Iekhsan Othman
MSMohamad F Shaikh
Mohamad F Shaikh

1 December 2019 in Pharmacological Research
Verified
Journal Article
Closed access
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel
Christina PiperiChristina Piperi
Christina Piperi

1 October 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Yam Nath PaudelYam Nath Paudel
Yam Nath Paudel
MSMohamad F Shaikh
Mohamad F Shaikh
SSSadia Shah
Sadia Shah
YKYatinesh Kumari
Yatinesh Kumari
IOIekhsan Othman
Iekhsan Othman